產品詳情
簡單介紹：
Anti-CAB39L抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-CAB39L抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-CAB39L
Cat. Number:
Anti-CAB39L抗體KL-6802R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Peutz-Jegers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. Mutations in the gene encoding the serine/threonine kinase LKB1 (also designated STK11) are the cause of PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-α Anti-CAB39L抗體(STRAD α) pseudo kinase and the calcium binding protein 39 (MO25, also known as CAB39). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK). CAB39L (calcium binding protein 39-like), also known as MO25L (MO25-like) or MO2L, is a 337 amino acid protein that is similar to MO25 and is found in the serum of nearly half of all patients diagnosed with acute monocytic leukemia. This suggests a role for CAB39L in carcinogenesis.
Also known as:
Antigen MLAA-34; Anti-CAB39L抗體CAB39-LIKE PROTEIN; Cab39l; Calcium-binding protein 39-like; CB39L_HUMAN; MO25-BETA; Mo25-like protein; MO2L; sarcoma antigen NY-SAR-79; U937-associated antigen.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human CAB39L.
●
Predicted Molecular Weight: 39kDa.
Storage:
Shipped at 4℃, Store at -20℃ Anti-CAB39L抗體(Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working dilutions must Anti-CAB39L抗體be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must Anti-CAB39L抗體be determined by the end user.
kl424Mu02 八聚體結合轉錄因子4(OCT4)多克隆抗體 Polyclonal Antibody to Octamer Binding Transcription Factor 4 (OCT4)
kl425Mu02 突觸素(SYP)多克隆抗體 Polyclonal Antibody to Synaptophysin (SYP)
kl431Mu02 顆粒酶M(GZMM)多克隆抗體 Polyclonal Antibody to Granzyme M (GZMM)
kl433Mu02 蛋白激酶Cδ(PKCδ)多克隆抗體 Polyclonal Antibody to Protein Kinase C Delta (PKCd)
kl437Mu02 雌**受體β(ERβ)多克隆抗體 Polyclonal Antibody to Estrogen Receptor Beta (ERb)
kl438Mu02 促生長**釋放**(GHRH)多克隆抗體 Polyclonal Antibody to Growth Hormone Releasing Hormone (GHRH)
kl439Mu02 蛋白激酶Cε(PKCε)多克隆抗體 Polyclonal Antibody to Protein Kinase C Epsilon (PKCe)
kl439Ra01 蛋白激酶Cε(PKCε)多克隆抗體 Polyclonal Antibody to Protein Kinase C Epsilon (PKCe)
kl442Mu02 阻抑素(PHB)多克隆抗體 Polyclonal Antibody to Prohibitin (PHB)
kl446Mu02 抑制素βC(INHβC)多克隆抗體 Polyclonal Antibody to Inhibin Beta C (INHbC)
kl448Gu01 胰島素(INS)多克隆抗體 Polyclonal Antibody to Insulin (INS)
kl448Mu02 胰島素(INS)多克隆抗體 Polyclonal Antibody to Insulin (INS)
kl449Mu02 胱天蛋白酶7(CASP7)多克隆抗體 Polyclonal Antibody to Caskle 7 (CASP7)
kl451Mu02 激肽釋放酶5(KLK5)多克隆抗體 Polyclonal Antibody to Kallikrein 5 (KLK5)
kl469Mu02 內皮脂肪酶(LIPG)多克隆抗體 Polyclonal Antibody to Likle, Endothelial (LIPG)
kl471Ga01 骨鈣素(OC)多克隆抗體 Polyclonal Antibody to Osteocalcin (OC)
kl471Mu02 骨鈣素(OC)多克隆抗體 Polyclonal Antibody to Osteocalcin (OC)
